Key Takeaways
- PAT guidance raised, earnings diversified: Management lifted FY27 PAT guidance to ₹775–800 crores (from ₹700–750 crores), while emphasizing earnings are now spread across South Africa, Brazil, and base US business rather than concentrated in any single product.
- Lenalidomide drag masks base business strength: YoY revenue declined on lower lenalidomide contribution, but the underlying base business including subsidiaries grew, and domestic formulations posted a 20% bump.
- Pomalidomide FTF underwhelmed by design: Shared first-to-file status with 5–6 competitors caused steep price erosion, so the 180-day exclusivity delivered no material earnings bump, a dynamic management calls "the nature of business."
- Cash pile deployed, more deals in sight: The rights issue proceeds repaid all acquisition debt; management is now pursuing at least one transaction seriously and holds first right of refusal on Adcock's remaining stake.
- What to watch next quarter: Carfilzomib launch economics (one sole FTF strength vs. the crowded 60 mg), any update on the acquisition being pursued, and whether Q3 delivers on the "looks good" promise embedded in the raised guidance.
Earnings Quality & Diversification
- Lenalidomide fade: The YoY revenue decline was largely attributable to lower lenalidomide revenue during the quarter, partially offset by growth in the base business including subsidiaries.
- Earnings base broadened: Management stressed that earnings are now fairly diversified across South Africa, Brazil, and base US business, even without lenalidomide in the numbers; in the past, earnings were highly concentrated by that single product.
- Profit Before Tax (ex-associates) doubled QoQ: This was an analyst's observation; management cautioned against reading quarter-to-quarter entity-level volatility in isolation, noting the business has cycles, different territories perform at different times, and there is an element of one-time orders and tenders.
- Other expenses stepped up: The increase was primarily driven by R&D spend, along with annual FDA facility fees, programme fees, and some legal expenses; R&D spend is very unpredictable quarter-on-quarter depending on milestone achievements.
- Adcock profit share dipped on one-offs: Q1 profits were very high due to seasonal flu season in South Africa (Q1 is the highest quarter for South Africa companies); Q2 had a one-off amortization of ~₹6.5 crores from purchase price allocation related to the additional 13.25% stake acquisition, plus a one-time VRS charge in one of the facilities.
- Crop Health Sciences turned marginally profitable: The segment achieved slight marginal profitability this quarter (₹10 lakh segmental profit), a positive quarter compared to Q1, while battling credit-related provisions and horrendous El Niño effects that constrained higher aspirations; still saw 15%–17% growth year-over-year.
Rajeev Nannapaneni: "I think the market appreciates more steady earnings, which are low risk, and they give a higher multiple for that. And I think our market is unwilling to appreciate high-risk, high-return sort of ideas."
US Generics & The FTF Model
- Pomalidomide shared FTF: Because there were 5 to 6 generic competitors in the first wave, price erosion was steep and the 180-day exclusivity produced no substantial earnings bump.
- Carfilzomib upcoming: One lower strength has sole FTF and is expected to do well; the other strength without exclusivity will launch later after the first wave; the 60 mg strength has multiple filers so value will not be exciting despite 180 days.
- Trabectedin upcoming: A smaller product; NATCO is one among two first-to-filers.
- Olaparib upcoming: Expected in the next few quarters in Brazil and Canada, subject to launch and legal challenge.
- Imbruvica settlement done: Settlement is approved in 30 months; exclusivity is believed to be sorted and covered.
- New Para IVs targeted: Management is targeting some Para IVs as sole FTFs and hopes to get the position and declare in the next few quarters.
- US generics philosophy: The US remains the most important market; it is a good business with limited competition, not great with many competitors; the model requires patience and running a basket of products.
Rajeev Nannapaneni: "Because there were 5 and 6 competitors, the price erosion was quite steep. So, even though we had 180 days, the earnings bump was not too substantial that could move the earnings. It is the way it is. That is the nature of business."
International Markets
- Canada poised for a breakout: Big launches are coming up in 2027; management expects "2027 will be a blowout year in Canada."
- Brazil delivered 80% growth this year and is expected to continue to do well next year.
- MENA region has done well; Canada has been stable.
- ROW growth drivers: Brazil, Middle East, and Canada, plus US exclusivities, will drive the Rest of the World business.
- South Africa portfolio build: Multiple products have been filed since acquiring the company about one year ago; regulatory approval takes about 2–3 years, so portfolio value is expected in the next 1.5–2 years.
- Adcock steady-state: PAT estimated at ~₹1.2 crore per month with seasonality; NATCO's consolidated PAT pickup expected at ₹55–60 crores after 49% share and ₹4–5 crore amortization; new CEO Mr. Rhulani (ex-Pfizer) has driven an uptick in the prescription business, which had been Adcock's weakness.
Rajeev Nannapaneni: "We have some big launches coming up in ‘2027. So, we expect ‘2027 will be a blowout year in Canada."
India Domestic & Semaglutide
- Domestic revenue elevated by one-off: Q2 domestic revenue of ₹145 Crore included stocking quantity of Semaglutide to partners, which is not repeatable; base domestic run rate is ₹130–135 Crore.
- Base business improved dramatically: A good 20% bump was driven by semaglutide (₹6–₹7 crore) and Risdiplam doing well; even excluding semaglutide stocking one-offs, the base business has improved.
- Onco price cut absorbed: The Onco price cut is not impacting sales significantly because distributor margin has been shrunk; any small marginal impact will be more than made up by volume increase.
- Semaglutide India is unprofitable: Pricing has been "really bad" as everybody is trying to get market share; the product is not profitable currently and no profits are seen in the near future; the hypothesis is to maintain 5–6% market share, wait for market size to increase over the next 2–3 years, then benefit from larger size.
- Domestic growth ambition: Internal target is to compound another 15%–20% next year also.
- Semaglutide global/ROW: Management declined to provide insight on the global semaglutide market or ROW expansion, stating the contract focus is primarily on US and regulated markets and they cannot give any insight about approval at this time.
Rajeev Nannapaneni: "But is it profitable? No. And do I see any profits coming in the near future? No. In the long run, maybe. I think it should do well as the size of Sema increases."
Capital Allocation & M&A
- Rights issue completed: Funds were used to reduce debt raised for the Adcock stake increase, with some kept for working capital payments and a possible acquisition; as of today, no loans exist.
- Adcock stake now 49%: NATCO acquired an additional 13.25% stake in July 2026; management stated the asset is so valuable that 49% is very meaningful; NATCO holds first right of refusal if the major shareholder chooses to sell the remaining 51%.
- Acquisition being pursued: Management is trying one transaction quite seriously and hopes to close it, subject to regulatory and agreement processes; expects to use some portion of the ₹2,250 crore net cash for transactions; no target size or P/E disclosed.
- eGenesis investment: Additional investment made, total now a little less than $25 million; one patient approaching almost one year without dialysis; monetization paths include India market license (discussions ongoing) or company IPO, both dependent on clinical trial data; next 12 months expected to bring clarity on data.
- Crop Health Sciences demerger delayed: The rights issue changed the capital structure, requiring resubmission to SEBI; timeline pushed out by 4 to 6 months, now expected by mid-year calendar year 2027.
- CapEx run rate: ₹300 crore spent in H1, higher than last year, driven by upgrading Chennai and Mekaguda API facilities, building new API blocks, upgrading formulation facilities, adding a new oncology line at Nagarjuna Sagar site (just started production), and setting up a cartridge line for semaglutide (ongoing, ready next financial year); expected run rate around ₹400 crore per year.
Rajeev Nannapaneni: "I think the asset is so valuable that 49% also is very meaningful. That’s why we took it."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| FY27 PAT | ₹775 to ₹800 crores (raised from ₹700–750 crores); Q3 looks good, Q4 is a little weak | FY27 |
| FY27 R&D spend | 8–10% of top line, around ₹300–350 crore | FY27 |
| Operating margin | Current level (~30.4% in Q2) considered a sustainable base going forward | Ongoing |
| Crop Health Sciences demerger | Mid-year Calendar Year 2027, subject to SEBI resubmission and NCLT process | Mid-CY2027 |
| FY28 base business growth | Around 10%–15%, excluding uncertain upsides from Para IVs, one-times, or exclusivities | FY28 |
| Domestic business growth | Internal target to compound 15%–20% next year | FY28 |
| Canada | Big launches coming; 2027 expected to be a blowout year | 2027 |
| CapEx run rate | Around ₹400 crore per year | Ongoing |
| Cartridge line (semaglutide) | Ready next financial year | FY28 |
| Adcock steady-state PAT pickup (consol) | ₹55–60 crores after 49% share and ₹4–5 crore amortization | Steady-state |
| Full-year standalone tax rate | 27%–27.2% | FY27 |
| Full-year consolidated tax rate | 29%–30% | FY27 |
| India business DSO | Expected to continue in 90–120 day range | Ongoing |
Key Metrics
| Metric | Q2 FY27 |
|---|---|
| Consolidated total revenue | ₹1,019.4 cr, +28.4% QoQ vs ₹794 cr in Q1 FY27; -30.3% YoY vs ₹1,463 cr in Q2 FY26 |
| EBITDA including other income | ₹310 cr, EBITDA margin of 30.4% |
| Consolidated profit after tax | ₹202.6 cr, -1.9% QoQ vs ₹206.5 cr in Q1 FY27 |
| Domestic formulation revenue | ₹145 cr, includes non-repeatable Semaglutide stocking; base run rate estimated at ₹130-135 cr |
| Brazil business revenue | ₹121 cr, +66% YoY |
| Brazil H1 FY27 revenue | nearly ₹300 cr |
| Adcock Ingram Q2 revenue | ₹1,344 cr |
| Adcock Ingram Q2 PAT | ₹80.5 cr |
| NATCO share of Adcock profit | ₹29.2 cr, based on 49% holding after purchase price allocation adjustment |
| Adcock stake | 49%, increased from 35.75% after acquiring additional 13.25% in July 2026 |
| FY27 PAT guidance (revised) | ₹775 to ₹800 cr, raised from earlier ₹700-750 cr |
| India Semaglutide volume share | 5% to 6% (management estimate) |
| India Semaglutide value share | 3% (management estimate) |
| Crop Health Sciences Q2 EBITDA | marginal profitability, approximately ₹10 lakh segmental profit |
| Agro business full-year EBITDA loss expectation | ~₹20 cr |
| R&D spend FY27 guidance | ₹300 to ₹350 cr, 8-10% of top line |
| CapEx H1 FY27 | ~₹300 cr |
| Full-year CapEx target | ~₹400 cr, typical run rate ₹350-400 cr |
| Net cash position | ~₹2,250 cr, after rights issue inflows and full loan repayment |
| Rights issue dilution | 10% overall |
| Consolidated tax rate Q2 | ~29%; full-year expected 29%-30% |
| Standalone tax rate Q2 | ~27%; full-year expected 27%-27.2% |
| India business DSO | 90-120 days |
| Investment in eGenesis | less than $25 million, substantial single-digit stake |